Introduction: Low-molecular-weight protein tyrosine phosphatase (LMW-PTP) expression affects carcinogenesis in various cancers and has been associated with determining the overall survival among men with metastatic hormone-naïve prostate cancer (mHNPC). In this study, we analyzed the value of LMWPTP for prediction of time to castration-resistant prostate cancer (CRPC) for men with mHNPC. Materials and Methods: We retrospectively enrolled 45 men with mHNPC who were diagnosed from 2003 to 2009. All patients had received androgen deprivation therapy as first-line treatment. Prostate cancer tissues (pre-treatment needle biopsies) were immunohistochemically stained for LMW-PTP. Multivariate analyses (Cox proportional hazard model) were used to correlate baseline clinical factors of age, prostate-specific antigen (PSA), Gleason scores, T stage, N stage, extent of disease on bone scan (EOD), LMW-PTP expression and time to CRPC. Continuous variables were classified as dichotomous. Results: Median age and PSA were 70.0 years and 87.8 ng/mL respectively. Median time to CRPC was 40.2 months. Median time to CRPC was significantly shorter in the high LMW-PTP group (14.8 months) than that in the low LMW-PTP group (86.3 months, p < 0.01). In multivariate analysis, age ≥70 years and high LMW-PTP expression were significant predictors of time to CRPC.

Keywords:
Low-molecular-weight protein tyrosine phosphatase, Metastatic hormone-naïve prostate cancer, Biomarker
1.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Eng J Med 2015; 373: 737–746.
2.
James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR: Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the stampede trial (mrc pr08, cruk/06/019). Eur Urol 2015; 67: 1028–1038.
3.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Ozguroglu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352–360.
4.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators: Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377: 338–351.
5.
Caselli A, Paoli P, Santi A, Mugnaioni C, Toti A, Camici G, Cirri P: Low molecular weight protein tyrosine phosphatase: multifaceted functions of an evolutionarily conserved enzyme. Biochim Biophys Acta 2016; 1864: 1339–1355.
6.
Ostanin K, Pokalsky C, Wang S, Van Etten RL: Cloning and characterization of a saccharomyces cerevisiae gene encoding the low molecular weight protein-tyrosine phosphatase. J Biol Chem 1995; 270: 18491–18499.
7.
Malentacchi F, Marzocchini R, Gelmini S, Orlando C, Serio M, Ramponi G, Raugei G: Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers. Biochem Biophys Res Commun 2005; 334: 875–883.
8.
Ohtaka M, Miyoshi Y, Kawahara T, Ohtake S, Yasui M, Uemura K, Yoneyama S, Hattori Y, Teranishi JI, Yokomizo Y, Uemura H, Miyamoto H, Yao M: Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naive prostate cancer. Urol Oncol 2017; 35: 607.e609–607.e614.
9.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee: The 2005 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228–1242.
10.
Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195–202.
11.
Remmele W, Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. Subjective grading (IRS). Pathol Res Pract 1993; 189: 862–866.
12.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008; 26: 1148–1159.
13.
Bryson GL, Massa H, Trask BJ, Van Etten RL: Gene structure, sequence, and chromosomal localization of the human red cell-type low-molecular-weight acid phosphotyrosyl phosphatase gene, ACP1. Genomics 1995; 30: 133–140.
14.
Raugei G, Ramponi G, Chiarugi P: Low molecular weight protein tyrosine phosphatases: small, but smart. Cell Mol Life Sci 2002; 59: 941–949.
15.
Chiarugi P, Cirri P, Raugei G, Camici G, Dolfi F, Berti A, Ramponi G: PDGF receptor as a specific in vivo target for low m(r) phosphotyrosine protein phosphatase. FEBS Lett 1995; 372: 49–53.
16.
Ramponi G, Manao G, Camici G, Cappugi G, Ruggiero M, Bottaro DP: The 18 kDa cytosolic acid phosphatase from bovine live has phosphotyrosine phosphatase activity on the autophosphorylated epidermal growth factor receptor. FEBS Lett 1989; 250: 469–473.
17.
Chiarugi P, Cirri P, Marra F, Raugei G, Camici G, Manao G, Ramponi G: LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signalling. Biochem Biophys Res Commun 1997; 238: 676–682.
18.
Alho I, Costa L, Bicho M, Coelho C: The role of low-molecular-weight protein tyrosine phosphatase (lmw-ptp acp1) in oncogenesis. Tumour Biol 2013; 34: 1979–1989.
19.
Chiarugi P, Taddei ML, Schiavone N, Papucci L, Giannoni E, Fiaschi T, Capaccioli S, Raugei G, Ramponi G: LMW-PTP is a positive regulator of tumor onset and growth. Oncogene 2004; 23: 3905–3914.
20.
Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, Pelizzaro-Rocha K, van Leenders GJLH, Jenster G, Aoyama H, Ferreira CV, Fuhler GM: Low-molecular-weight protein tyrosine phosphatase predicts prostate cancer outcome by increasing the metastatic potential. Eur Urol 2016; 69: 710–719.
21.
Miyoshi Y, Noguchi K, Yanagisawa M, Taguri M, Morita S, Ikeda I, Fujinami K, Miura T, Kobayashi K, Uemura H: Nomogram for overall survival of japanese patients with bone-metastatic prostate cancer. BMC Cancer 2015; 15: 338.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.